pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,031 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT783Endpoints586BioPharma Dive224onclive165BioSpace59Fierce Biotech57raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • STAT+: Medicare still won’t say how much covering obesity drugs will cost
    Older adults on Medicare can get Wegovy and Zepbound for $50 a month, starting in July. But the agency still is not sharing how much this will cost taxpayers.
    STAT · 1mo ago↗ source
  • The hidden history of BPC-157, a favorite MAHA peptide
    A compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using peptides.
    STAT · 1mo ago↗ source
  • STAT+: No Surprises Act arbitration rule could worsen flood of provider disputes
    The arbitration process has protected patients but generated financial windfalls for some clinicians.
    STAT · 1mo ago↗ source
← prev
page 23 of 42
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • STAT+: A standing ovation for RevMed, and caution for Akeso
    ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
    STAT · 1mo ago↗ source
  • Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
    Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
    STAT · 1mo ago↗ source
  • STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
    Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.
    STAT · 1mo ago↗ source
  • STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
    A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
    STAT · 1mo ago↗ source
  • STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
    By doing hormone therapy upfront in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.
    STAT · 1mo ago↗ source
  • STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
    ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
    STAT · 1mo ago↗ source
  • STAT+: China competition, ‘destruction’ at FDA give agency chance to restructure, Rick Pazdur says
    Rick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well, let's rebuild it as…
    STAT · 1mo ago↗ source
  • STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
    CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
    STAT · 1mo ago↗ source
  • STAT+: As Ebola outbreak grows, Trump administration veers from previous government playbook
    Trump officials are disregarding the Biden administration's detailed pandemic plans in favor of their own strategy.
    STAT · 1mo ago↗ source
  • STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
    You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here.   We’re ASCOmaxxing. Rest…
    STAT · 1mo ago↗ source
  • STAT+: Trump administration seeks to overhaul federal grantmaking process, alarming researchers
    The Trump administration has released a sweeping proposal to overhaul the bedrock regulation for all federal grants.
    STAT · 1mo ago↗ source
  • Kenya court suspends U.S. plan for Ebola quarantine facility for Americans
    A court in Kenya on Friday suspended a U.S. plan to establish a quarantine facility for Americans exposed to a rare type of Ebola virus spreading in northeastern Congo.
    STAT · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
    Pharma updates from the Pharmalot campus via the Pharmalittle newsletter
    STAT · 1mo ago↗ source
  • STAT+: Allogene CEO David Chang stepping down
    Pfizer invests billions to buy Chinese drugs, WHO maps experimental response to Ebola outbreak, and other biotech news from The Readout
    STAT · 1mo ago↗ source
  • STAT+: Massachusetts sues UnitedHealth, alleging fraud in state’s Medicaid plans for seniors
    State AG alleges UnitedHealthcare claimed some members were sicker to boost its profits.
    STAT · 1mo ago↗ source
  • Which vaccines will curb the Ebola outbreak? WHO debates
    The growing Ebola outbreak, the unknowns of microdosing GLP-1s, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    STAT · 1mo ago↗ source
  • STAT+: The woman behind the world’s biggest longevity competition
    Jamie Justice of XPRIZE Healthspan on the most promising research and "purely scammy" treatments in the world of longevity.
    STAT · 1mo ago↗ source
  • Opinion: I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’
    Long term, we don’t know what tiny doses of GLP-1s for cosmetic weight loss can do, writes a weight-loss doctor.
    STAT · 1mo ago↗ source
  • STAT+: As Ebola outbreak in Central Africa grows, the U.S. turns itself into a fortress
    The U.S. is taking extraordinary steps to keep Ebola out. But its policies may create risks for Americans infected overseas and discourage volunteers from responding to the outbreak.
    STAT · 1mo ago↗ source
  • STAT+: 23andMe offers to connect users’ DNA data with medical records
    23andMe is partnering with HealthEx to allow users to import their medical records, the company said Tuesday at STAT Breakthrough Summit West.
    STAT · 2mo ago↗ source
  • STAT+: Marc Tessier-Lavigne addresses new book’s allegations about his conduct in Stanford misconduct case
    Former Stanford President Marc Tessier-Lavigne responded publicly for the first time, at a STAT event Tuesday, to allegations in a new book about why he was forced to resign.
    STAT · 2mo ago↗ source